Prescriber's Corner
Glasdegib: A Novel Hedgehog Pathway Inhibitor for Acute Myeloid Leukemia
Daniel L. Thompson,(1) PharmD Candidate, and Donald C. Moore,(2) PharmD, BCPS, BCOP, DPLA
From (1)Wingate University School of Pharmacy, Wingate, North Carolina; (2)Levine Cancer Institute, Atrium Health, Concord, North Carolina
Authors’ disclosures of conflicts of interest are found at the end of this article.
Correspondence to: Donald C. Moore, PharmD, BCPS, BCOP, DPLA, Levine Cancer Institute – Department of Pharmacy, Atrium Health,
100 Medical Park Drive, Concord, NC 28025.
E-mail: donald.moore1@carolinashealthcare.org
J Adv Pract Oncol 2020;11(2):196–200 |
https://doi.org/10.6004/jadpro.2020.11.2.8 |
© 2020 Harborside™
ABSTRACT
Acute myeloid leukemia (AML) is an aggressive myeloid disorder that is associated with a generally poor prognosis. Effective treatment options have been limited for older patients with AML who are not able to undergo intensive remission induction chemotherapy due to advanced age or comorbidities. New and novel agents are needed to improve treatment outcomes for this patient population. Glasdegib is a novel Hedgehog signaling pathway inhibitor approved by the U.S. Food & Drug Administration for the treatment of patients with newly diagnosed AML who are 75 years of age or older or who have comorbidities that preclude intensive induction chemotherapy. Glasdegib is approved in combination with low-dose cytarabine (LDAC). This approval is based on the results of a multicenter, open-label, randomized trial of glasdegib plus LDAC vs. LDAC monotherapy in which the addition of glasdegib resulted in an improvement in median overall survival.
For access to the full length article, please
sign in.
